Introduction
In rare disease research, identifying genetic variants is only the first step; elucidating their pathogenic mechanisms is often more critical. Sometimes, an "exclusion" prediction from a bioinformatics tool can also guide research in the right direction. A recent study on Dubin-Johnson Syndrome (DJS) cleverly utilized the analysis results from the RDDC tool. In the study, RDDC predicted that a novel ABCC2 gene missense variant p.R393W does not affect RNA splicing. This "negative" conclusion successfully guided the research team to focus on the protein level, ultimately confirming for the first time that this variant causes disease through accelerated proteasomal degradation pathways, revealing a novel molecular mechanism of DJS.
Research Challenge: Different Pathogenic Pathways of Compound Heterozygous Variants
The study subjects were twins with DJS. Whole exome sequencing (WES) revealed they carried compound heterozygous variants in the ABCC2 gene: a paternal missense mutation c.1177C>T (p.R393W) and a maternal missense mutation c.3632T>C (p.L1211P).
To fully understand the pathogenic mechanism in these twins, it was necessary to separately elucidate how these two variants disrupt the function of the MRP2 protein (encoded by ABCC2). For the p.R393W variant, does it cause disease by affecting RNA splicing or by altering protein structure/stability?
RDDC's "Exclusion" Contribution: Ruling Out Splicing Anomalies
To first assess whether p.R393W might cause disease by interfering with RNA splicing, the research team used RDDC's RNA splicing prediction tool. The analysis results showed that this variant is unlikely to significantly affect the splicing process of ABCC2 mRNA.
This "negative" prediction result was highly significant. It enabled the research team to confidently shift their research focus from the RNA level to the protein level, exploring whether this missense variant directly affects the MRP2 protein itself.
Experimental Validation: Confirming Proteasomal Degradation Mechanism
After excluding the possibility of splicing anomalies, the research team conducted a series of functional experiments. The results revealed:
- In cells expressing the
p.R393Wvariant, MRP2 protein levels were significantly reduced (only 27%-52% of wild-type levels). - The half-life of the mutant protein was markedly shortened (2.5 hours vs. 5 hours for wild-type).
- Treatment with proteasome inhibitor MG132 restored the levels of the mutant protein.
These experimental results clearly demonstrated that the p.R393W variant does not exert its pathogenic effect through affecting splicing, but rather through accelerating MRP2 protein degradation via the ubiquitin-proteasome pathway. The study also found that the p.L1211P variant causes disease by affecting protein cellular membrane localization, further revealing the diversity of DJS pathogenic mechanisms.
Case Implications
This case demonstrates the flexible application value of bioinformatics tools like RDDC in pathogenic mechanism research. Even when prediction results are "negative" (such as excluding splicing anomalies), they can provide valuable clues for subsequent research, effectively narrowing the exploration scope and improving experimental efficiency. Through RDDC-assisted exclusion of splicing mechanisms, the research team discovered for the first time a novel pattern of ABCC2 p.R393W variant causing disease through proteasomal degradation, providing a more comprehensive understanding for molecular diagnosis and genetic counseling of DJS.
Content Source and Disclaimer
This article is a compilation and interpretation of the following scientific research, aimed at demonstrating the application of RDDC bioinformatics tools. All research data and conclusions belong to the original authors and publications.
Original Literature:
Zhang H, Zhang Y, Gao Y, et al. ABCC2 p.R393W variant contributes to Dubin- Johnson syndrome by targeting MRP2 to proteasome degradation. Journal of Medical Genetics. 2024 Mar 7. doi: 10.1136/jmg-2023-109783. Epub ahead of print.
Literature Link: https://pubmed.ncbi.nlm.nih.gov/39944748/
